AffiliationPaterson Institute for Cancer Research, Manchester, UK. email@example.com
MetadataShow full item record
AbstractDT-diaphorase (DTD) is an obligate two-electron reductase which bioactivates chemotherapeutic quinones. DTD levels are elevated in a number of tumour types, including non-small cell lung carcinoma, colorectal carcinoma, liver cancers and breast carcinomas, when compared to the surrounding normal tissue. The differential in DTD between tumour and normal tissue should allow targeted activation of chemotherapeutic quinones in the tumour whilst minimising normal tissue toxicity. The prototypical bioreductive drug is Mitomycin C (MMC) which is widely used in clinical practice. However, MMC is actually a relatively poor substrate for DTD and its metabolism is pH-dependent. Other bioreductive drugs have failed because of poor solubility and inability to surpass other agents in use. RH1, a novel diaziridinylbenzoquinone, is a more efficient substrate for DTD. It has been demonstrated to have anti-tumour effects both in vitro and in vivo and demonstrates a relationship between DTD expression levels and drug response. RH1 has recently entered a phase I clinical trial in solid tumours under the auspices of Cancer Research UK. Recent work has demonstrated that DTD is present in the nucleus and is associated with both p53 and the heat shock protein, HSP-70. Furthermore, DTD is inducible by several non-toxic compounds and therefore much interest has focussed on increasing the differential in DTD levels between tumour and normal tissues.
CitationDT-diaphorase: a target for new anticancer drugs. 2004, 30 (5):437-49 Cancer Treat. Rev.
JournalCancer Treatment Reviews
- Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
- Authors: Phillips RM, Burger AM, Loadman PM, Jarrett CM, Swaine DJ, Fiebig HH
- Issue date: 2000 Nov 15
- Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
- Authors: Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D
- Issue date: 1995 Sep
- DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C.
- Authors: Saeki S, Nishiyama M, Toge T
- Issue date: 1995 Sep
- Authors: Mikami K, Shirakusa T, Tsuruo T
- Issue date: 1997 Sep
- Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
- Authors: Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, Au JL
- Issue date: 2001 May